GR3025476T3 - Synthetic particulate vectors and method for preparing same - Google Patents

Synthetic particulate vectors and method for preparing same

Info

Publication number
GR3025476T3
GR3025476T3 GR970403125T GR970403125T GR3025476T3 GR 3025476 T3 GR3025476 T3 GR 3025476T3 GR 970403125 T GR970403125 T GR 970403125T GR 970403125 T GR970403125 T GR 970403125T GR 3025476 T3 GR3025476 T3 GR 3025476T3
Authority
GR
Greece
Prior art keywords
preparing same
synthetic particulate
particulate vectors
core
synthetic
Prior art date
Application number
GR970403125T
Other languages
English (en)
Inventor
Daniel Samain
Pascal Delrieu
Jo Lle Gibilaro
Roselyne Dirson
Monique Cervilla
Miguel Ignacio De
Li Ding
Frederique Nguyen
Nadine Soulet
Corinne Soler
Original Assignee
Biovector Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovector Therapeutics Sa filed Critical Biovector Therapeutics Sa
Publication of GR3025476T3 publication Critical patent/GR3025476T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
    • A23L27/72—Encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR970403125T 1993-03-02 1997-11-26 Synthetic particulate vectors and method for preparing same GR3025476T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9302397A FR2702160B1 (fr) 1993-03-02 1993-03-02 Vecteurs particulaires synthétiques et procédé de préparation.
PCT/FR1994/000228 WO1994020078A1 (fr) 1993-03-02 1994-03-01 Vecteurs particulaires synthetiques et procede de preparation

Publications (1)

Publication Number Publication Date
GR3025476T3 true GR3025476T3 (en) 1998-02-27

Family

ID=9444575

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970403125T GR3025476T3 (en) 1993-03-02 1997-11-26 Synthetic particulate vectors and method for preparing same

Country Status (12)

Country Link
US (2) US6013284A (el)
EP (3) EP0787479A1 (el)
JP (1) JPH08507765A (el)
KR (1) KR100317751B1 (el)
AT (2) ATE158179T1 (el)
DE (2) DE69405718T2 (el)
DK (2) DK0687173T3 (el)
ES (2) ES2186815T3 (el)
FR (1) FR2702160B1 (el)
GR (1) GR3025476T3 (el)
PT (1) PT782851E (el)
WO (1) WO1994020078A1 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723849B1 (fr) * 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
FR2753902B1 (fr) 1996-09-27 1999-04-02 Ioualalen Karim Nouveau type de matrice ionique biodegradable de polarite interne modulable a polymere greffe
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
FR2757768B1 (fr) * 1996-12-27 1999-04-02 Biovector Therapeutics Sa Vecteur particulaire homeocharge et composition pharmaceutique ou cosmetique le contenant
FR2757876B1 (fr) * 1996-12-27 1999-04-09 Biovector Therapeutics Sa Conjuges d'un vecteur particulaire et d'oligonucleotides, leur procede de preparation et les compositions pharmaceutiques les contenant
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
AU7201998A (en) * 1997-05-06 1998-11-27 Zhi Liu Drug delivery system
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7101575B2 (en) * 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
EA005140B1 (ru) 1999-04-02 2004-12-30 Корикса Корпорейшн Соединения и способы для лечения и диагностики рака легкого
AUPQ326499A0 (en) * 1999-10-05 1999-10-28 Commonwealth Scientific And Industrial Research Organisation Nanoparticle films
DE10001172A1 (de) * 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001068828A2 (en) 2000-03-13 2001-09-20 Engene, Inc. Compositions and methods for regulated protein expression in gut
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
FR2808193B1 (fr) * 2000-04-26 2004-05-07 Biovector Therapeutics Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers
AU6815901A (en) * 2000-06-02 2001-12-17 Zycos Inc Delivery systems for bioactive agents
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
CN101863930A (zh) 2003-01-06 2010-10-20 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US6809197B1 (en) 2003-06-11 2004-10-26 Mgp Ingredients, Inc. Emulsion stabilizing starch products
US7166305B2 (en) * 2003-06-11 2007-01-23 Mgp Ingredients, Inc. Polyvalent metal-substituted starch products
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
DE102004013637A1 (de) * 2004-03-19 2005-10-13 Capsulution Nanoscience Ag Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln
EP2497831B1 (en) 2004-05-25 2014-07-16 Oregon Health and Science University TB vaccination using HCMV-based vaccine vectors
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
DE102005037844A1 (de) * 2005-08-04 2007-04-05 Intendis Gmbh Wasserfreies Mehr-Phasen-Gel-System
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
WO2007101681A1 (en) 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
WO2007117657A2 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP1897538A1 (en) * 2006-08-23 2008-03-12 Stallergenes Sa Formulations for antigen-specific tolerance induction
FR2921253B1 (fr) * 2007-09-26 2012-11-16 Lvmh Rech Composition cosmetique sous la forme d'une emulsion comprenant une phase aqueuse continue et une phase grasse dispersee et son procede de preparation
US8619257B2 (en) 2007-12-13 2013-12-31 Kimberley-Clark Worldwide, Inc. Recombinant bacteriophage for detection of nosocomial infection
NZ603997A (en) 2007-12-27 2013-02-22 Baxter Int Chemically Modified Factor IX
WO2009153798A1 (en) * 2008-06-16 2009-12-23 Natco Pharma Limited Cross-linked dextrin as a tablet disintegrant/excipient
JP5903268B2 (ja) * 2008-07-24 2016-04-13 アモーレパシフィック コーポレイションＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ 多層ラメラ顆粒、及びこれを含有する皮膚外用剤組成物
JP2013505022A (ja) 2009-09-16 2013-02-14 バクサート インコーポレーティッド Ｈ１ｎ１感染を予防するための免疫戦略の方法
WO2011060233A1 (en) 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
WO2016134002A1 (en) * 2015-02-18 2016-08-25 Memorial Sloan Kettering Cancer Center Compositions and methods for nanoparticle-based drug delivery and imaging
BR112018070948A2 (pt) 2016-04-13 2019-01-29 Orimabs Ltd. anticorpos anti-psma e utilização dos mesmos
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP7448954B2 (ja) 2018-02-21 2024-03-13 ザ ユニバーシティー オブ モンタナ ジアリールトレハロース化合物及びその使用
WO2019169313A1 (en) 2018-03-02 2019-09-06 The University Of Montana Immunogenic trehalose compounds and uses thereof
US12496340B2 (en) 2019-05-23 2025-12-16 The University Of Montana Vaccine adjuvants based on TLR receptor ligands
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
FR3112284B1 (fr) * 2020-07-10 2024-02-09 Vaxinano Procede de preparation d’une composition vaccinale a partir d’antigenes lyophilises
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
US20240409638A1 (en) 2021-10-07 2024-12-12 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
CN119213021A (zh) 2022-02-10 2024-12-27 艾菲赛尔治疗株式会社 与CD40L特异性结合的Stefin A蛋白变体及其用途
IL316289A (en) 2022-04-29 2024-12-01 Purinomia Biotech Inc Methods and compositions for treating diseases and disorders driven by eosinophils
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
EP4656648A1 (en) 2024-05-31 2025-12-03 Consejo Superior De Investigaciones Científicas Immunomodulatory thiourea and urea carbohydrate compounds and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
EP0093757A1 (en) * 1981-11-12 1983-11-16 Ulf SCHRÖDER Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
US4839111A (en) * 1987-02-02 1989-06-13 The University Of Tennessee Research Corporation Preparation of solid core liposomes
JPH0745385B2 (ja) * 1987-03-31 1995-05-17 協和醗酵工業株式会社 毛髪用化粧料組成物
US5132285A (en) * 1988-04-26 1992-07-21 National Starch And Chemical Investment Holding Corporation Method for thickening or stabilizing aqueous media with polyamphoteric polysaccharides
FR2631826B1 (fr) * 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
GB8820332D0 (en) * 1988-08-26 1988-09-28 Allied Colloids Ltd Graft copolymers
JP2528087B2 (ja) * 1988-11-16 1996-08-28 キッコーマン株式会社 美白化粧料
EP0460101A4 (en) 1989-02-24 1992-04-15 Immunotherapeutics, Inc. Immobilized cytokines
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
SE9002017D0 (sv) * 1990-06-06 1990-06-06 Kabivitrum Ab Process for manufacture of matrices
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FR2677249B1 (fr) * 1991-06-04 1995-03-17 Biovecteurs As Vecteur particulaire biodegradable et procede de synthese.
FR2677272B1 (fr) * 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
EP0610441A4 (en) * 1991-10-29 1996-01-10 Clover Cons Ltd CROSSLINKABLE POLYSACCHARIDES, POLYCATIONS AND LIPIDS CAN BE USED TO ENCODE AND DISPENSE MEDICINAL PRODUCTS.
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung

Also Published As

Publication number Publication date
ATE158179T1 (de) 1997-10-15
FR2702160B1 (fr) 1995-06-02
EP0782851B1 (fr) 2002-11-27
US6013284A (en) 2000-01-11
DE69431807D1 (de) 2003-01-09
US20020168408A1 (en) 2002-11-14
EP0687173A1 (fr) 1995-12-20
US6759060B2 (en) 2004-07-06
ES2186815T3 (es) 2003-05-16
DE69405718T2 (de) 1998-03-19
DE69431807T2 (de) 2003-11-06
EP0787479A1 (fr) 1997-08-06
DK0687173T3 (da) 1998-04-14
EP0687173B1 (fr) 1997-09-17
DK0782851T3 (da) 2003-03-24
PT782851E (pt) 2003-04-30
ES2108432T3 (es) 1997-12-16
KR960700695A (ko) 1996-02-24
WO1994020078A1 (fr) 1994-09-15
EP0782851A1 (fr) 1997-07-09
KR100317751B1 (ko) 2002-06-20
JPH08507765A (ja) 1996-08-20
DE69405718D1 (de) 1997-10-23
ATE228352T1 (de) 2002-12-15
FR2702160A1 (fr) 1994-09-09

Similar Documents

Publication Publication Date Title
GR3025476T3 (en) Synthetic particulate vectors and method for preparing same
GB2219109B (en) Manufacturing apparatus incorporating an inference planning system
AU8749491A (en) Hydrophilised solid surface, method for the production thereof, and agent therefor
EP0642105A3 (en) Method and apparatus for generating or modifying a model of a solid object.
IT1198789B (it) Procedimento per la trasmissione di informazioni e/o di comandi,in particolare per l'uso in ferrovia
AU2472888A (en) Method of solidification and encapsulation using core-shell polymer particles
AU625718B2 (en) Tracheobronchodilator
AU626474B2 (en) Motor controller with an improved stopping technique
ITTO940470A0 (it) Dispositivo d'atterramento e d'ormeggio per un dirigibile.
DE69114444D1 (de) Steuersystem für Roboter mit Beschleunigungs- und Verzögerungszeitkonstanten.
AU5269893A (en) Medical laser apparatus and diagnosing/curing apparatus using the medical laser apparatus
TW332831B (en) Heterobenopyran compounds
AU7451391A (en) Programming system and method, and programming device and terminals constituting the system
FI960429L (fi) Menetelmä 1,4-butaanidiolin valmistamiseksi
EP0667661A3 (en) Semiconductor laser and manufacturing process.
WO1993018168A3 (en) Transgenic wheat
EP0453948A3 (en) Method for producing 1,4-butanediol
DE69426889D1 (de) Carbonatharz mit verbesserter fliessfaehigkeit, verfahren zu seiner herstellung und daraus hergestelltes duennwandiges teil
IT8840113A0 (it) Copertura,in particolare per cassoni di veicoli quali autocarri e simili
AU2637492A (en) Artificial standard and control sera, processes for the preparation thereof and the use thereof
EP0684613A3 (en) Semiconductor polymer element, manufacturing method and device comprising it.
GB8830075D0 (en) Non-attritive method for making polyethylene particles,particles obtainable by the method and their use
PT89996A (pt) Processo para a preparacao de 3-(2,3,4,5,6-pentafluorofenoxi)-8-azabiciclo{3.2.1}octanos
GB8830074D0 (en) Non-attritive method for making polyamide particles,particles obtainable by the method and their use
EP0633567A3 (en) Capstan engine suspension.